Opthea Limited
Overview
Opthea Limited is a biopharmaceutical company focused on developing and commercializing therapies to treat highly prevalent and progressive retinal diseases. The company's lead product candidate, OPT-302, targets VEGF-C/D to improve outcomes in patients with wet age-related macular degeneration (wet AMD).
Therapeutic areas
OphthalmologyRetinal Diseases
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Opthea Limited in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.